Zacks: Analysts Anticipate Accelerate Diagnostics Inc (AXDX) to Announce -$0.41 Earnings Per Share

Equities analysts forecast that Accelerate Diagnostics Inc (NASDAQ:AXDX) will announce ($0.41) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Accelerate Diagnostics’ earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.39). Accelerate Diagnostics posted earnings per share of ($0.27) in the same quarter last year, which indicates a negative year-over-year growth rate of 51.9%. The company is expected to announce its next earnings report on Thursday, February 21st.

On average, analysts expect that Accelerate Diagnostics will report full year earnings of ($1.61) per share for the current year, with EPS estimates ranging from ($1.63) to ($1.60). For the next fiscal year, analysts expect that the firm will report earnings of ($1.00) per share, with EPS estimates ranging from ($1.44) to ($0.27). Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Accelerate Diagnostics.

Accelerate Diagnostics (NASDAQ:AXDX) last announced its earnings results on Tuesday, November 6th. The medical research company reported ($0.41) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.41). The business had revenue of $1.36 million during the quarter, compared to the consensus estimate of $2.89 million. Accelerate Diagnostics had a negative net margin of 1,365.75% and a negative return on equity of 81.76%.

A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Thursday, August 9th. Piper Jaffray Companies reiterated a “buy” rating and issued a $24.00 target price on shares of Accelerate Diagnostics in a report on Tuesday, August 7th. BidaskClub downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Friday, October 5th. Finally, JPMorgan Chase & Co. downgraded shares of Accelerate Diagnostics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $25.00 to $16.00 in a report on Wednesday, November 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $20.00.

In related news, Director John Patience acquired 10,000 shares of the business’s stock in a transaction dated Thursday, November 8th. The shares were purchased at an average price of $14.96 per share, for a total transaction of $149,600.00. Following the completion of the acquisition, the director now directly owns 44,670 shares in the company, valued at approximately $668,263.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 49.30% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Credit Suisse AG increased its holdings in shares of Accelerate Diagnostics by 5.0% during the third quarter. Credit Suisse AG now owns 3,653,892 shares of the medical research company’s stock valued at $83,856,000 after acquiring an additional 173,289 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Accelerate Diagnostics by 2.0% during the third quarter. BlackRock Inc. now owns 1,785,849 shares of the medical research company’s stock valued at $40,983,000 after acquiring an additional 34,958 shares in the last quarter. Vanguard Group Inc. increased its holdings in Accelerate Diagnostics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,291,417 shares of the medical research company’s stock worth $29,638,000 after buying an additional 10,601 shares during the period. Blair William & Co. IL increased its holdings in Accelerate Diagnostics by 36.2% in the 3rd quarter. Blair William & Co. IL now owns 878,655 shares of the medical research company’s stock worth $20,165,000 after buying an additional 233,408 shares during the period. Finally, Chicago Capital LLC increased its holdings in Accelerate Diagnostics by 17.1% in the 3rd quarter. Chicago Capital LLC now owns 630,053 shares of the medical research company’s stock worth $14,460,000 after buying an additional 91,862 shares during the period. Hedge funds and other institutional investors own 47.13% of the company’s stock.

Shares of Accelerate Diagnostics stock opened at $13.50 on Friday. The stock has a market capitalization of $724.64 million, a price-to-earnings ratio of -11.64 and a beta of 2.49. The company has a quick ratio of 33.54, a current ratio of 35.26 and a debt-to-equity ratio of 1.52. Accelerate Diagnostics has a one year low of $12.70 and a one year high of $30.35.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Recommended Story: How to read a candlestick chart

Get a free copy of the Zacks research report on Accelerate Diagnostics (AXDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply